• / Free eNewsletters & Magazine
  • / My Account
Home>TherapeuticsMD Announces Multiple Presentations Related to TX-004HR and TX-001HR at NAMS 2017

TherapeuticsMD Announces Multiple Presentations Related to TX-004HR and TX-001HR at NAMS 2017

TherapeuticsMD Announces Multiple Presentations Related to TX-004HR and TX-001HR at NAMS 2017

10/05/2017

TherapeuticsMD Announces Multiple Presentations Related to TX-004HR and TX-001HR at NAMS 2017

Nine total presentations reviewing the detailed findings of the complete TX-004HR and TX-001HR clinical programs

Five oral presentations reviewing the detailed findings of the pivotal Phase 3 Replenish Trial of TX-001HR

TherapeuticsMD, Inc. (NYSE American:TXMD), an innovative women’s healthcare company, today announced the schedule of nine presentations at NAMS 2017, the annual meeting of the North American Menopause Society, in Philadelphia, Pennsylvania, October 11-14, related to TX-004HR, the company’s investigational applicator-free vaginal estradiol softgel capsule in development for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause, and TX-001HR, the company’s investigational bio-identical hormone therapy combination of 17ß-estradiol and progesterone in a single, oral softgel, for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause.

Five oral presentations reviewing the detailed findings of the pivotal Phase 3 Replenish Trial will provide new data supporting the overall safety and efficacy of TX-001HR. These data will include additional MENQOL (quality of life) scores, uterine bleeding rates, and sleep outcomes.

“We are pleased to present additional new data from the Replenish Trial at the annual meeting of the North American Menopause Society, further supporting the safety and efficacy of TX-001HR as the first bio-identical combination hormone therapy of estradiol and progesterone in a large, well-controlled, randomized clinical trial,” said TherapeuticsMD Chief Medical Officer Sebastian Mirkin, M.D. “If approved, TX-001HR would provide a validated new treatment option for the millions of postmenopausal women who are currently taking unapproved compounded hormones for the treatment of moderate to severe vasomotor symptoms.”

The posters and presentations will be made available on the Investors & Media section of the company’s website at www.therapeuticsmd.com. Details include:

TX-004HR Oral Presentations and Posters

©2017 Morningstar Advisor. All right reserved.